180 related articles for article (PubMed ID: 24967688)
1. Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment.
Liu N; Tengstrand EA; Chourb L; Hsieh FY
Toxicol Appl Pharmacol; 2014 Sep; 279(3):467-476. PubMed ID: 24967688
[TBL] [Abstract][Full Text] [Related]
2. Qualified method for the estimation of di-18:1 bis(monoacylglycero)phosphate in urine, a noninvasive biomarker to monitor drug-induced phospholipidosis.
Murali BV; Kurawattimath V; Bhutani P; Onorato J; Naikodi SB; Kole P; Rajanna PK
Bioanalysis; 2020 Aug; 12(15):1049-1059. PubMed ID: 32735140
[No Abstract] [Full Text] [Related]
3. Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats.
Thompson KL; Zhang J; Stewart S; Rosenzweig BA; Shea K; Mans D; Colatsky T
Toxicol Lett; 2012 Sep; 213(2):285-91. PubMed ID: 22828012
[TBL] [Abstract][Full Text] [Related]
4. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
Tengstrand EA; Miwa GT; Hsieh FY
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
[TBL] [Abstract][Full Text] [Related]
5. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP.
Mesens N; Desmidt M; Verheyen GR; Starckx S; Damsch S; De Vries R; Verhemeldonck M; Van Gompel J; Lampo A; Lammens L
Toxicol Pathol; 2012 Apr; 40(3):491-503. PubMed ID: 22291062
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat.
Thompson KL; Haskins K; Rosenzweig BA; Stewart S; Zhang J; Peters D; Knapton A; Rouse R; Mans D; Colatsky T
Int J Toxicol; 2012; 31(1):14-24. PubMed ID: 22267869
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of di-docosahexaenoyl (C22:6)-bis(monoacylglycerol) phosphate in unlabelled and C-13 labelled forms for use as a biomarker of drug induced phospholipidosis.
Hickey MJ; Lindqvist J; Ha YH; Andersson H; Elmore CS
J Labelled Comp Radiopharm; 2019 Sep; 62(11):695-706. PubMed ID: 30793359
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers to monitor drug-induced phospholipidosis.
Baronas ET; Lee JW; Alden C; Hsieh FY
Toxicol Appl Pharmacol; 2007 Jan; 218(1):72-8. PubMed ID: 17156806
[TBL] [Abstract][Full Text] [Related]
9. A multiplexed UPLC-MS/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis.
Tengstrand E; Zhang H; Liu N; Dunn K; Hsieh F
Toxicol Appl Pharmacol; 2019 Mar; 366():54-63. PubMed ID: 30653977
[TBL] [Abstract][Full Text] [Related]
10. Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans.
Grabner GF; Fawzy N; Pribasnig MA; Trieb M; Taschler U; Holzer M; Schweiger M; Wolinski H; Kolb D; Horvath A; Breinbauer R; Rülicke T; Rabl R; Lass A; Stadlbauer V; Hutter-Paier B; Stauber RE; Fickert P; Zechner R; Marsche G; Eichmann TO; Zimmermann R
J Lipid Res; 2019 May; 60(5):1020-1031. PubMed ID: 30894461
[TBL] [Abstract][Full Text] [Related]
11. Bis(monoacylglycero)phosphate, a peculiar phospholipid to control the fate of cholesterol: Implications in pathology.
Hullin-Matsuda F; Luquain-Costaz C; Bouvier J; Delton-Vandenbroucke I
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):313-24. PubMed ID: 19857945
[TBL] [Abstract][Full Text] [Related]
12. Bis(monoacylglycero)phosphate, a new lipid signature of endosome-derived extracellular vesicles.
Rabia M; Leuzy V; Soulage C; Durand A; Fourmaux B; Errazuriz-Cerda E; Köffel R; Draeger A; Colosetti P; Jalabert A; Di Filippo M; Villard-Garon A; Bergerot C; Luquain-Costaz C; Moulin P; Rome S; Delton I; Hullin-Matsuda F
Biochimie; 2020 Nov; 178():26-38. PubMed ID: 32659447
[TBL] [Abstract][Full Text] [Related]
13. Imaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with Phospholipidosis.
Sakurai T; Kamio K; Sasaki K; Nishimoto T; Yamaguchi JI; Sasaki M; Tsutsumi S
Am J Pathol; 2018 Sep; 188(9):1993-2003. PubMed ID: 29981744
[TBL] [Abstract][Full Text] [Related]
14. Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver.
Sanoh S; Yamachika Y; Tamura Y; Kotake Y; Yoshizane Y; Ishida Y; Tateno C; Ohta S
J Toxicol Sci; 2017; 42(5):589-596. PubMed ID: 28904294
[TBL] [Abstract][Full Text] [Related]
15. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced phospholipidosis: are there functional consequences?
Reasor MJ; Kacew S
Exp Biol Med (Maywood); 2001 Oct; 226(9):825-30. PubMed ID: 11568304
[TBL] [Abstract][Full Text] [Related]
17. Bis(monoacylglycero)phosphate: a secondary storage lipid in the gangliosidoses.
Akgoc Z; Sena-Esteves M; Martin DR; Han X; d'Azzo A; Seyfried TN
J Lipid Res; 2015 May; 56(5):1006-13. PubMed ID: 25795792
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
19. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect.
Pauluhn J
Toxicology; 2005 Feb; 207(1):59-72. PubMed ID: 15590122
[TBL] [Abstract][Full Text] [Related]
20. Bis(monoacylglycero)phosphate, an important actor in the host endocytic machinery hijacked by SARS-CoV-2 and related viruses.
Luquain-Costaz C; Rabia M; Hullin-Matsuda F; Delton I
Biochimie; 2020 Dec; 179():247-256. PubMed ID: 33159981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
